KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Merck (MRK) EBITDA (2016 - 2025)

Merck (MRK) has disclosed EBITDA for 17 consecutive years, with -$2.1 billion as the latest value for Q4 2025.

  • Quarterly EBITDA fell 723.1% to -$2.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 billion through Dec 2025, down 1.22% year-over-year, with the annual reading at $4.7 billion for FY2025, 1.22% down from the prior year.
  • EBITDA for Q4 2025 was -$2.1 billion at Merck, down from $2.9 billion in the prior quarter.
  • The five-year high for EBITDA was $2.9 billion in Q3 2025, with the low at -$9.4 billion in Q2 2023.
  • Average EBITDA over 5 years is -$276.2 million, with a median of $22.5 million recorded in 2021.
  • The sharpest move saw EBITDA crashed 23016.67% in 2021, then surged 28800.0% in 2025.
  • Over 5 years, EBITDA stood at $35.0 million in 2021, then plummeted by 1151.43% to -$368.0 million in 2022, then tumbled by 1519.02% to -$6.0 billion in 2023, then soared by 105.74% to $342.0 million in 2024, then crashed by 723.1% to -$2.1 billion in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$2.1 billion, $2.9 billion, and $1.4 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.